Home > News > Nexttobe extends loan to Oasmia
December 2nd, 2013
Nexttobe extends loan to Oasmia
Abstract:
Oasmia Pharmaceutical AB develops new generations
of drugs in the field of human and veterinary oncology. The company's product
development aims to create and manufacture novel nanoparticle formulations and
drug-delivery systems based on well-established cytostatics which, in
comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The company's product development is
based on its proprietary in-house research and company patents. Oasmia is
listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX,
ISIN SE0000722365).
Source:
wsj.com
Related News Press |
News and information
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
Announcements
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |